全球基因治疗市场 – 行业趋势及 2031 年预测

基因治疗市场分析及规模

在基因治疗市场，创新疗法利用遗传物质从根本上治疗疾病，提供潜在的治愈方法，而不是症状管理。这种变革性方法有望治疗从遗传疾病到癌症等各种疾病，通过提供个性化和有针对性的干预措施彻底改变医疗保健，最终改善患者的生活质量和预后。

例如，2022 年 12 月，日本厚生劳动省批准了 Kite Pharma, Inc. 和第一三共株式会社联合研发的 CAR T 细胞疗法 Yescarta，用于治疗复发/难治性大 B 细胞淋巴瘤。该疗法仅针对未接受过针对 CD19 的 CAR T 细胞治疗的患者。                 

Data Bridge Market Research 分析称，2023 年全球基因治疗市场规模为 86.8 亿美元，预计到 2031 年将达到 333.1 亿美元，预测期内（2024 年至 2031 年）的复合年增长率为 18.3%。这表明市场价值。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

基因治疗市场范围和细分

Market Definition

Gene therapy is a medical approach to treating genetic disorders by introducing, removing, or modifying specific genes within a patient's cells. This therapeutic method holds the potential for addressing inherited diseases such as cystic fibrosis or cancer by targeting the root genetic cause. It offers promise for personalized medicine and has shown encouraging results in clinical trials.            

Global Gene Therapy Market Dynamics

Drivers

• Rising Prevalence of Genetic Disorders

The surge in genetic disorders such as cystic fibrosis, sickle cell anemia, and muscular dystrophy is driving the need for gene therapy treatments. This rising incidence underscores the demand for innovative therapeutic approaches. Gene therapy offers potential solutions by targeting the root causes of these disorders, presenting a promising avenue for addressing unmet medical needs in affected populations.

• Advancements in Gene Editing Technologies

Innovations such as hemophilia gene therapy and CRISPR-Cas9 have revolutionized gene editing, improving precision, efficiency, and affordability. This transformation propels growth in the gene therapy market by facilitating targeted genetic modifications for disease treatment. These advancements offer more effective therapies, spurring investment and driving the creation of innovative gene therapy solutions for diverse medical conditions.

For instance, in March 2021, the USFDA approved Abecma (idecabtagene vicleucel), a pioneering cell-based gene therapy for adults with multiple myeloma who haven't responded to or relapsed after at least four prior treatments. It marks the FDA's first approval of a cell-based gene therapy for this form of cancer, offering a new treatment avenue.

Opportunities

• Growing Personalized Medicine Approach

Gene therapy facilitates personalized treatment by targeting genetic mutations and offering tailored solutions for individual patients. This approach, honing in on the unique genetic makeup of each person, drives market expansion by providing highly effective and customized therapies, thus revolutionizing the landscape of medical treatment.

• Rise in Strategic Acquisition and Partnership Among Organizations

Organizations are increasingly forming strategic partnerships to develop gene therapy products for detecting genetic disorders. Collaborations facilitate the development of new technologies and platforms for disease detection. Long-term agreements enable companies to offer dynamic pricing of gene therapy products, catering to consumer demand. These partnerships create opportunities for mutual growth and benefit in the market.

For instance, in January 2023, Spark Therapeutics and Neurochase initiated a strategic collaboration to integrate Neurochase's specialized delivery technology with Spark's AAV platform for selected gene therapies targeting rare CNS disorders. Neurochase brings expertise in direct drug delivery, enhancing Spark's capabilities for effective treatment development.

Restraints/Challenges

• Concern About Immune Responses

Immune responses to viral vectors or foreign gene products can impede gene therapy efficacy and cause adverse events. Strategies to address this challenge include immunomodulatory interventions and engineered vectors designed to evade immune detection. Overcoming these responses is crucial for ensuring the safety and effectiveness of gene therapy treatments. 

• High Development Costs

Gene therapy's substantial research and development costs stem from intricate manufacturing, extensive clinical trials, and stringent regulatory demands. These financial hurdles pose challenges for companies, limiting investment capacity and potentially hindering innovation and market accessibility. Overcoming the high costs of gene therapy is essential for progressing the field and ensuring wider accessibility for patients.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In December 2023, Libmeldy received approval from the Swiss Agency for Therapeutic Products to treat early-onset metachromatic leukodystrophy, marking a significant advancement in addressing this rare disorder's therapeutic needs
• In May 2023, Krystal Biotech's VYJUVEK gene therapy gained approval for treating Dystrophic Epidermolysis Bullosa, offering hope to patients with this debilitating condition
• In January 2023, Voyager Therapeutics and Neurocrine Biosciences initiated a strategic collaboration to commercialize and develop Voyager's GBA1 program and other innovative gene therapies targeting neurological disorders, promising advancements in this critical field of medicine
• In August 2022, the USFDA approved Zynteglo (betibeglogene autotemcel) as the first cell-based gene therapy for treating beta-thalassemia in adults and children. The approval of Zynteglo gene therapy is driving market growth, fueled by heightened research and development in gene therapy. This breakthrough promises innovative treatments for genetic disorders, marking a significant advancement in the field of medical science
• In December 2022, Ferring Pharmaceuticals saw FDA approval for Adstiladrin, a gene therapy for high-risk, BCG-unresponsive non-muscle invasive bladder cancer. This novel therapy, based on an adenovirus vector, targets adult patients with carcinoma in situ, with or without papillary tumors, bolstering the company's product range and therapeutic options

Gene Therapy Market Scope

The market is segmented on the basis of vector type, method, gene type, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Vector Type

• Viral Vector
• Non-Viral Vector

 Method

• Ex-Vivo
• In-Vivo

 Gene Type

• Antigen
• Cytokine
• Tumor Suppressor
• Suicide
• Deficiency
• Growth factors
• Receptors
• Others

 Application

• Oncological Disorders
• Cardiovascular Diseases
• Infectious Diseases
• Rare Diseases
• Neurological Disorders
• Other Diseases

 End User

• Cancer Institutes
• Hospitals
• Research institutes
• Others

Global Gene Therapy Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, vector type, method, gene type, application, and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the market, propelled by rising R&D investments. The U.S., led by key players such as Novartis AG and Kite Pharma, holds significant regional control, fostering market growth and innovation.

Europe is expected to be fastest growing in the gene therapy market, propelled by Germany's mass production and emerging market demand. Expansion initiatives bolster its dominance, meeting the growing need for innovative treatments and solidifying its position as a global leader in biotechnology.

亚太地区预计将主导基因治疗市场，其中中国是主要市场。越来越多的客户青睐微创医疗程序，推动该地区的增长。这一趋势与基因治疗的先进治疗前景相一致，为其应用创造了有利的环境。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

该市场还为您提供每个国家/地区资本设备医疗支出增长、全球自身免疫性疾病诊断市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。

竞争格局和全球基因治疗市场份额分析

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

• 诺华公司（瑞士）
• 吉利德科学公司（美国）
• uniQure NV (荷兰)
• Oxford Biomedica PLC（英国）
• Spark Therapeutics, Inc.（美国）
• 思博诺（中国）
• bluebird bio, Inc.（美国）
• 上海三维生物技术有限公司 (中国)
• Biogen（美国）
• Dendreon Pharmaceuticals LLC（美国）
• 安进公司 (美国)
• AnGes, Inc.（日本）
• Enzyvant Therapeutics GmbH（瑞士）
• Epeius Biotechnologies Corp.（美国）
• 安斯泰来制药株式会社 (日本)
• 美国基因技术公司（美国）
• BioMarin (美国)

SKU-24569